We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IRadimed (IRMD) Raised to Strong Buy on Estimate Revisions
Read MoreHide Full Article
On Jun 17, Zacks Investment Research raised IRadimed Corp. (IRMD - Free Report) to a Zacks Rank #1 (Strong Buy).
Why this upgrade?
The upgrade was driven by impressive first-quarter 2016 results. Adjusted earnings of 9 cents outpaced the Zacks Consensus Estimate by a penny (5.56%). Notably, the company has outperformed the Zacks Consensus Estimate in the last four quarters, with an average beat of 7.64%.
Revenues surged 28.2% from the year-ago quarter to $9 million and was in line with the Zacks Consensus Estimate. The growth was driven by strong demand for IV pumps. The company sold 263 IV pumps as compared to 217 pumps in the year-ago quarter.
We believe that sales force expansion and increasing production output will drive results in the rest of 2016. Additionally, the anticipated launch of the patient monitoring system (third quarter-international; fourth quarter-the U.S.) is a key catalyst.
Based on these bullish factors, IRadimed raised its full-year 2016 earnings guidance. The company now forecasts adjusted earnings in the range of 88 cents to 90 cents, up from the earlier guided range of 83–85 cents. Revenues forecast remained unchanged at $39–$40 million.
Estimate Revision
The Zacks Consensus Estimate for the second quarter is currently pegged at 21 cents, up a penny over the last 60 days.
Over the same time frame, the Zacks Consensus Estimate for full-year 2016 moved up by a nickel to 88 cents per share.
Other Stocks to Consider
One may also consider other favorably ranked stocks like Cryolife Inc , Masimo Corporation (MASI - Free Report) and Mesa Labs Inc (MLAB - Free Report) in the same space. All the three stocks sport a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
IRadimed (IRMD) Raised to Strong Buy on Estimate Revisions
On Jun 17, Zacks Investment Research raised IRadimed Corp. (IRMD - Free Report) to a Zacks Rank #1 (Strong Buy).
Why this upgrade?
The upgrade was driven by impressive first-quarter 2016 results. Adjusted earnings of 9 cents outpaced the Zacks Consensus Estimate by a penny (5.56%). Notably, the company has outperformed the Zacks Consensus Estimate in the last four quarters, with an average beat of 7.64%.
Revenues surged 28.2% from the year-ago quarter to $9 million and was in line with the Zacks Consensus Estimate. The growth was driven by strong demand for IV pumps. The company sold 263 IV pumps as compared to 217 pumps in the year-ago quarter.
IRADIMED CORP Price and Consensus
IRADIMED CORP Price and Consensus | IRADIMED CORP Quote
Key Growth Factors
We believe that sales force expansion and increasing production output will drive results in the rest of 2016. Additionally, the anticipated launch of the patient monitoring system (third quarter-international; fourth quarter-the U.S.) is a key catalyst.
Based on these bullish factors, IRadimed raised its full-year 2016 earnings guidance. The company now forecasts adjusted earnings in the range of 88 cents to 90 cents, up from the earlier guided range of 83–85 cents. Revenues forecast remained unchanged at $39–$40 million.
Estimate Revision
The Zacks Consensus Estimate for the second quarter is currently pegged at 21 cents, up a penny over the last 60 days.
Over the same time frame, the Zacks Consensus Estimate for full-year 2016 moved up by a nickel to 88 cents per share.
Other Stocks to Consider
One may also consider other favorably ranked stocks like Cryolife Inc , Masimo Corporation (MASI - Free Report) and Mesa Labs Inc (MLAB - Free Report) in the same space. All the three stocks sport a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>